Corvus Pharmaceuticals, Inc. Proceeds from Issuance of Convertible Preferred Stock
Corvus Pharmaceuticals, Inc. (CRVS) reported Proceeds from Issuance of Convertible Preferred Stock of $95.57 million for the 12-month period ending 2015-12-31, per its 10-K filed 2018-03-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2018-03-01
- Corvus Pharmaceuticals, Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2015-12-31 was $0.00.
- Corvus Pharmaceuticals, Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2015-09-30 was $74.84M.
- Corvus Pharmaceuticals, Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2015-06-30 was $16.73M.
- Corvus Pharmaceuticals, Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2015-03-31 was $4.00M.
- Corvus Pharmaceuticals, Inc. proceeds from issuance of convertible preferred stock for fiscal 2015 was $95.57M.
| Period end | Proceeds from Issuance of Convertible Preferred Stock 3 month | Proceeds from Issuance of Convertible Preferred Stock 6 month | Proceeds from Issuance of Convertible Preferred Stock 9 month | Proceeds from Issuance of Convertible Preferred Stock 11 month | Proceeds from Issuance of Convertible Preferred Stock 12 month |
|---|---|---|---|---|---|
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $74.84M derived: sum of 2 quarters · filed 2018-03-01 | $91.57M derived: sum of 3 quarters · filed 2018-03-01 | $95.57M 10-K · filed 2018-03-01 | |
| 2015-09-30 | $74.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $91.57M derived: sum of 2 quarters · filed 2016-11-03 | $95.57M 10-Q · filed 2016-11-03 | ||
| 2015-06-30 | $16.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $20.73M 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | $4.00M 10-Q · filed 2016-05-05 | ||||
| 2014-12-31 | $12.61M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |